A new class of glucose-lowering therapy for type 2 diabetes: the latest development in the incretin arena

Bain, Stephen C.; Min, Thinzar

doi:10.1016/s0140-6736(23)01182-0

Cited by 2 publications

(1 citation statement)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Semaglutide was the first GLP‐1RA also available for once‐daily oral administration through combination with a permeation enhancer 222 . Recent phase III trials demonstrated greater weight loss of oral semaglutide, at 50 mg once daily compared to placebo in overweight /obesity after 68 weeks 223 or at 25 and 50 mg once daily compared to the 14 mg dose in controlled type 2 diabetes 224 (Figures 3 and 4).…”

Section: Introductionmentioning

confidence: 99%

Role of lifestyle and glucagon‐like peptide‐1 receptor agonists for weight loss in obesity, type 2 diabetes and steatotic liver diseases

Giannakogeorgou,

Roden

2024

Aliment Pharmacol Ther

View full text Add to dashboard Cite

SummaryBackgroundThe current obesity pandemic has given rise to associated comorbidities and complications, including type 2 diabetes and metabolic dysfunction‐associated steatotic liver disease (MASLD). During the last decade, certain glucagon‐like peptide 1 receptor agonists (GLP‐1RA), originally developed as antihyperglycemic drugs, also demonstrated efficacy for weight loss.AimsTo review shared pathophysiologic features of common metabolic diseases and compare therapeutic strategies to reduce body weight and related complications.MethodsWe performed an extensive literature research to describe the effects of lifestyle modification, first‐generation anti‐obesity drugs, and GLP‐1RA on weight loss in humans with obesity, type 2 diabetes and MASLD.ResultsUntil recently, treatment of obesity has been limited to lifestyle modification, which offer moderate degree and sustainability of weight loss. The few approved first‐generation anti‐obesity drugs are either limited to short term use or to certain forms of obesity. Some GLP‐1RA significantly decrease caloric intake and body weight. Liraglutide and semaglutide have therefore been approved for treating people with obesity. They also lead to a reduction of hepatic fat content and inflammation in people with biopsy‐confirmed MASLD. Possible limitations comprise adverse effects, treatment adherence and persistence.ConclusionCertain GLP‐1RA are superior to lifestyle modification and first‐generation anti‐obesity drugs in inducing weight loss. They have therefore markedly changed the portfolio of obesity treatment with additional beneficial effects on steatotic liver disease.

show abstract

Section: Introductionmentioning

confidence: 99%